It’s been more than a year since the start of the Food & Drug Administration’s “Breakthrough” therapy designation, and there are still a lot of questions from drug sponsors about the specifics of the program. At every public discussion on FDA’s new Breakthrough therapy designation – and there have been quite a few recently – industry executives have peppered agency officials with questions about which products qualify as a “Breakthrough,” often including specifics about their particular development programs.
Hey, check out all the research scientist jobs. Post your resume today!
